When.com Web Search

Search results

1. Results From The WOW.Com Content Network

2. How a new FDA-approved drug can — and can’t — help people ...

   www.aol.com/fda-approved-drug-t-help-121600044.html

   And 1 in 3 adults ages 65 and older dies with it or another form of dementia, according to the Alzheimer’s Association. ... Just because the FDA approves a drug doesn’t necessarily mean that ...

3. Janus kinase inhibitor - Wikipedia

   en.wikipedia.org/wiki/Janus_kinase_inhibitor

   A Janus kinase inhibitor, also known as JAK inhibitor or jakinib, [1] is a type of immune modulating medication, which inhibits the activity of one or more of the Janus kinase family of enzymes (JAK1, JAK2, JAK3, TYK2), thereby interfering with the JAK-STAT signaling pathway in lymphocytes.

4. Top aging expert says these 4 FDA-approved drugs hold promise ...

   www.aol.com/finance/global-aging-doctor-says-4...

   New research also suggests the inhibitors may reduce the risk of dementia in people with type 2 diabetes after longer-term use. Bisphosphonates Bisphosphonates, scoring 11 out of 12, treat ...

5. Ruxolitinib - Wikipedia

   en.wikipedia.org/wiki/Ruxolitinib

   Ruxolitinib (sold under the brand names Jakafi and Jakavi among others, and as Opzelura in cream form) is a medication used for the treatment of intermediate or high-risk myelofibrosis, [6] a type of myeloproliferative neoplasm that affects the bone marrow; [11] [12] polycythemia vera, when there has been an inadequate response to or intolerance of hydroxyurea; [6] [13] and steroid-refractory ...

6. Pacritinib - Wikipedia

   en.wikipedia.org/wiki/Pacritinib

   Pacritinib, sold under the brand name Vonjo, is an anti-cancer medication used to treat myelofibrosis. [1] [2] It is a macrocyclic protein kinase inhibitor.It mainly inhibits Janus kinase 2 (JAK2) and Fms-like tyrosine kinase 3\CD135 (FLT3).

7. A Common Drug Could Lower Your Dementia Risk By 35 ... - AOL

   www.aol.com/common-drug-could-lower-dementia...

   A recent study found that a class of medications called SGLT-2 inhibitors—which does not include Ozempic or similar drugs like Zepbound—significantly lowered the risk of dementia in people ...